Literature DB >> 22762358

Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines.

Luana Lionetto1, Barbara Casolla, Fabiola Mastropietri, Lidia D'Alonzo, Andrea Negro, Maurizio Simmaco, Paolo Martelletti.   

Abstract

INTRODUCTION: Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction. The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies. Acute treatments consist of triptan, ergot, opioid, antiemetic and NSAIDs. AREAS COVERED: This article discusses pharmacodynamics and pharmacokinetics of zolmitriptan . The data were obtained by searching the following keywords in MEDLINE: zolmitriptan, pharmacokinetics, pharmacodynamics, triptans, migraine, menstrual-related migraine, cluster headache, relatively to the period 1989 - 2012. EXPERT OPINION: Zolmitriptan has been considered effective treatment in the acute phase of migraine, menstrual-related migraine and cluster headache attacks. Pharmacokinetic parameters may vary as a consequence of gender differences, inter- and intra-subjects variability and delivery system. Zolmitriptan was developed with the aim of obtaining a lipophilic compound in order to be more rapidly absorbed and centrally active. Pharmacologically, pharmacokinetic parameters are responsible for its wide efficacy and the limited adverse effect profile.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762358     DOI: 10.1517/17425255.2012.701618

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  3 in total

Review 1.  Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans.

Authors:  Flavia Franconi; Cinzia Finocchi; Gianni Allais; Stefano Omboni; Vincenzo Tullo; Ilaria Campesi; Giorgio Reggiardo; Chiara Benedetto; Gennaro Bussone
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

Review 2.  Triptans in prevention of menstrual migraine: a systematic review with meta-analysis.

Authors:  Yong Hu; Xiaofei Guan; Lin Fan; Lingjing Jin
Journal:  J Headache Pain       Date:  2013-01-30       Impact factor: 7.277

3.  Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.

Authors:  Haiyang Xu; Wei Han; Jinghua Wang; Mingxian Li
Journal:  J Headache Pain       Date:  2016-12-12       Impact factor: 7.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.